Affiliation:
1. Department of Pediatrics, Indiana University School of Medicine , Indianapolis, IN 46202 , USA
2. Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, TX 77030 , USA
Abstract
Abstract
Context
Obesity is prevalent in type 1 diabetes (T1D) and is problematic with higher risk for diabetes complications. It is unknown to what extent gut microbiome changes are associated with obesity and T1D.
Objective
This work aimed to describe the gut microbiome and microbial metabolite changes associated with obesity in T1D. We hypothesized statistically significant gut microbial and metabolite differences in lean T1D youth (body mass index [BMI]: 5%-<85%) vs those with obesity (BMI: ≥95%).
Methods
We analyzed stool samples for gut microbial (using metagenomic shotgun sequencing) and short-chain fatty acid (SCFA) differences in lean (n = 27) and obese (n = 21) T1D youth in a pilot study. The mean ± SD age was 15.3 ± 2.2 years, glycated hemoglobin A1c 7.8 ± 1.3%, diabetes duration 5.1 ± 4.4 years, 42.0% female, and 94.0% were White.
Results
Bacterial community composition showed between sample diversity differences (β-diversity) by BMI group (P = .013). There was a higher ratio of Prevotella to Bacteroides in the obese group (P = .0058). There was a differential distribution of significantly abundant taxa in either the lean or obese groups, including increased relative abundance of Prevotella copri, among other taxa in the obese group. Functional profiling showed an upregulation of branched-chain amino acid (BCAA) biosynthesis in the obese group and upregulation of BCAA degradation, tyrosine metabolism, and secondary bile acid biosynthesis in the lean group. Stool SCFAs were higher in the obese vs the lean group (P < .05 for all).
Conclusion
Our findings identify a gut microbiome and microbial metabolite signature associated with obesity in T1D. These findings could help identify gut microbiome–targeted therapies to manage obesity in T1D.
Funder
National Institutes of Health
National Center for Advancing Translational Sciences
Indiana University Health Values Fund
Indiana Clinical and Translational Sciences Institute
Clinical and Translational Sciences Award
Pilot and Feasibility Grant
Indiana Center for Diabetes and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Doris Duke Charitable Foundation
Retain Clinical Scientists Collaborative Grant Program
The John Templeton Foundation